BMS builds case for cardiovascular drug mavacamten with new analysis - PMLiVE

EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19 - PMLiVE

Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit - PMLiVE

Extra doses will be used for UK's planned booster vaccination programme in autumn - News - PharmaTimes

Test will be used for T cell testing in study, which is evaluating different combinations of COVID-19 vaccines - News - PharmaTimes

Administration of large molecules can trigger an immune response in patients, leading to the production of anti-drug-antibodies (ADA). Neutralizing antibodies (NAb) are a specific type of ADA that reduce the therapeutic effect by interfering with the drug-target interaction, thereby neutralizing drug’s efficacy, and causing unwanted adverse effects. Thus, it is crucial to detect the levels of NAb in serum of patients.
Cell-based assays (CBA) and competitive ligand binding assays (cLBA) are developed to detect NAb for immunogenicity assessment. One major challenge in the development of NAb assays is sufficient drug tolerance, because of the presence of high levels of residual drug in patient’s serum.
In this 45-minute interactive webinar, Dr Regina Bruyns, Senior Scientist Immunology at NUVISAN and Sripriya Jaganathan, Bioanalytical Scientist, Immunoassays at NUVISAN will discuss suitable cLBA formats and sample pre-treatment strategies for NAb detection. We will also present intricate analytical hurdles, which we encountered in attempts to remove the drug in cLBA, and we will also show how to overcome the problems caused by drug interference in detecting NAb.
Their presentation will cover:
• Neutralizing anti-drug antibodies
• Competitive ligand binding assay formats to detect NAb
• Challenges in NAb detection
• Approaches to minimize drug interference in NAb assays
• Live Q & A session
[Can't join?] Don't worry, register anyway, the slides and recording will be sent to you after the webinar.
[What's next?] After registering, a confirmation email will be sent to your email address.

Administration of large molecules can trigger an immune response in patients, leading to the production of anti-drug-antibodies (ADA). Neutralizing antibodies (NAb) are a specific type of ADA that reduce the therapeutic effect by interfering with the drug-target interaction, thereby neutralizing drug’s efficacy, and causing unwanted adverse effects. Thus, it is crucial to detect the levels of NAb in serum of patients.
Cell-based assays (CBA) and competitive ligand binding assays (cLBA) are developed to detect NAb for immunogenicity assessment. One major challenge in the development of NAb assays is sufficient drug tolerance, because of the presence of high levels of residual drug in patient’s serum.
In this 45-minute interactive webinar, Dr Regina Bruyns, Senior Scientist Immunology at NUVISAN and Sripriya Jaganathan, Bioanalytical Scientist, Immunoassays at NUVISAN will discuss suitable cLBA formats and sample pre-treatment strategies for NAb detection. We will also present intricate analytical hurdles, which we encountered in attempts to remove the drug in cLBA, and we will also show how to overcome the problems caused by drug interference in detecting NAb.
Their presentation will cover:
• Neutralizing anti-drug antibodies
• Competitive ligand binding assay formats to detect NAb
• Challenges in NAb detection
• Approaches to minimize drug interference in NAb assays
• Live Q & A session
[Can't join?] Don't worry, register anyway, the slides and recording will be sent to you after the webinar.
[What's next?] After registering, a confirmation email will be sent to your email address.